Anti-miRNA-221 sensitizes human colorectal carcinoma cells to radiation by upregulating PTEN

World Journal of Gastroenterology

Volumn 19, Issue 48, 2013, Pages 9307-9317

  Xue, Qi ^a   Sun, Kai ^a   Deng, Hai Jun ^a   Lei, Shang Tong ^a   Dong, Jing Qing ^a   Li, Guo Xin ^a  

^a FIRST MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Colorectal carcinoma; MiR 221; Phosphatase and tensin homolog deleted on chromosome 10; Radiosensitivity

Indexed keywords

MICRORNA 221; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME 10; COLONY FORMATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; MTT ASSAY; PROTEIN EXPRESSION; RADIATION DOSE; RADIATION EXPOSURE; RADIOSENSITIVITY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; WESTERN BLOTTING;

COLORECTAL CARCINOMA; MIR-221; PHOSPHATASE AND TENSIN HOMOLOG DELETED ON CHROMOSOME 10; RADIOSENSITIVITY;

CACO-2 CELLS; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, RADIATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HT29 CELLS; HUMANS; MICRORNAS; OLIGONUCLEOTIDES, ANTISENSE; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RADIATION TOLERANCE; RNA INTERFERENCE; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSFECTION; UP-REGULATION;

EID: 84891405412     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i48.9307     Document Type: Article

References (36)

1. Puente Gutiérrez JJ, Marín Moreno MA, Domínguez Jiménez JL, Bernal Blanco E, Díaz Iglesias JM. Effectiveness of a colonoscopic screening programme in first-degree relatives of patients with colorectal cancer. Colorectal Dis 2011; 13: e145-e153 [PMID: 21564467 DOI: 10.1111/j.1463-1318.2011.02577.x]
2. Rundle AG, Lebwohl B, Vogel R, Levine S, Neugut AI. Colonoscopic screening in average-risk individuals ages 40 to 49 vs 50 to 59 years. Gastroenterology 2008; 134: 1311-1315 [PMID: 18471508 DOI: 10.1053/j.gastro.2008.02.032]
3. Deng Q, Huang CM, Chen N, Li L, Wang XD, Zhang W, Bi F, Tang QL, Li ZP, Wang W. Chemotherapy and radiotherapy downregulate the activity and expression of DNA methyltransferase and enhance Bcl-2/E1B-19-kDa interacting protein-3-induced apoptosis in human colorectal cancer cells. Chemotherapy 2012; 58: 445-453 [PMID: 23364257 DOI:10.1159/000345916]
4. Colibaseanu DT, Mathis KL, Abdelsattar ZM, Larson DW, Haddock MG, Dozois EJ. Is curative resection and long-term survival possible for locally re-recurrent colorectal cancer in the pelvis? Dis Colon Rectum 2013; 56: 14-19 [PMID: 23222275 DOI: 10.1097/DCR.0b013e3182741929]
5. Sun K, Deng HJ, Lei ST, Dong JQ, Li GX. miRNA-338-3-p suppresses cell growth of human colorectal carcinoma by targeting smoothened. World J Gastroenterol 2013; 19: 2197-2207 [PMID: 23599646 DOI: 10.3748/wjg.v19.i14.2197]
6. Anindo MI, Yaqinuddin A. Insights into the potential use of microRNAs as biomarker in cancer. Int J Surg 2012; 10: 443-449 [PMID: 22906693 DOI: 10.1016/j.ijsu.2012.08.006]
7. Fabian MR, Sonenberg N. The mechanics of miRNAmediated gene silencing: a look under the hood of miRISC. Nat Struct Mol Biol 2012; 19: 586-593 [PMID: 22664986 DOI:10.1038/nsmb.2296]
8. Fabbri M. miRNAs as molecular biomarkers of cancer. Expert Rev Mol Diagn 2010; 10: 435-444 [PMID: 20465498 DOI:10.1586/erm.10.27]
9. Zhou YL, Liu C, Dai XX, Zhang XH, Wang OC. Overexpression of miR-221 is associated with aggressive clinicopathologic characteristics and the BRAF mutation in papillary thyroid carcinomas. Med Oncol 2012; 29: 3360-3366 [PMID: 22855362 DOI: 10.1007/s12032-012-0315-8]
10. Sun K, Wang W, Zeng JJ, Wu CT, Lei ST, Li GX. MicroRNA-221 inhibits CDKN1C/p57 expression in human colorectal carcinoma. Acta Pharmacol Sin 2011; 32: 375-384 [PMID: 21278784 DOI: 10.1038/aps.2010.206]
11. Jagan I, Fatehullah A, Deevi RK, Bingham V, Campbell FC. Rescue of glandular dysmorphogenesis in PTEN-deficient colorectal cancer epithelium by PPARγ-targeted therapy. Oncogene 2013; 32: 1305-1315 [PMID: 22543585 DOI: 10.1038/ onc.2012.140]
12. Xiong B, Cheng Y, Ma L, Zhang C. MiR-21 regulates biological behavior through the PTEN/PI-3 K/Akt signaling pathway in human colorectal cancer cells. Int J Oncol 2013; 42: 219-228 [PMID: 23174819 DOI: 10.3892/ijo.2012.1707]
13. Zhao G, Cai C, Yang T, Qiu X, Liao B, Li W, Ji Z, Zhao J, Zhao H, Guo M, Ma Q, Xiao C, Fan Q, Ma B. MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/ Akt pathway in human osteosarcoma. PLoS One 2013; 8: e53906 [PMID: 23372675 DOI: 10.1371/journal.pone.0053906]
14. Zhang C, Kang C, Wang P, Cao Y, Lv Z, Yu S, Wang G, Zhang A, Jia Z, Han L, Yang C, Ishiyama H, Teh BS, Xu B, Pu P. MicroRNA-221 and-222 regulate radiation sensitivity by targeting the PTEN pathway. Int J Radiat Oncol Biol Phys 2011; 80: 240-248 [PMID: 21481725 DOI: 10.1016/ j.ijrobp.2010.12.049]
15. Mirnezami AH, Sagar PM, Kavanagh D, Witherspoon P, Lee P, Winter D. Clinical algorithms for the surgical management of locally recurrent rectal cancer. Dis Colon Rectum 2010; 53: 1248-1257 [PMID: 20706067 DOI: 10.1007/ DCR.0b013e3181e10b0e]
16. Dellas K, Reese T, Richter M, Arnold D, Dunst J. Concurrent chemoradiation of metastases with capecitabine and oxaliplatin and 3D-CRT in patients with oligometastatic colorectal cancer: results of a phase I study. Radiat Oncol 2012; 7: 83 [PMID: 22681700 DOI: 10.1186/1748-717X-7-83]
17. Caravatta L, Padula GD, Picardi V, Macchia G, Deodato F, Massaccesi M, Sofo L, Pacelli F, Rotondi F, Cecere G, Sallustio G, Di Lullo L, Piscopo A, Mignogna S, Bonomo P, Cellini N, Valentini V, Morganti AG. Concomitant boost radiotherapy and multidrug chemotherapy in the neoadjuvant treatment of locally advanced rectal cancer: results of a phase II study. Acta Oncol 2011; 50: 1151-1157 [PMID: 21851185 DOI:10.3109/0284186X.2011.582880]
18. Ferenschild FT, Vermaas M, Verhoef C, Ansink AC, Kirkels WJ, Eggermont AM, de Wilt JH. Total pelvic exenteration for primary and recurrent malignancies. World J Surg 2009; 33: 1502-1508 [PMID: 19421811 DOI: 10.1007/s00268-009-0066-7]
19. You YN, Roses RE, Chang GJ, Rodriguez-Bigas MA, Feig BW, Slack R, Nguyen S, Skibber JM. Multimodality salvage of recurrent disease after local excision for rectal cancer. Dis Colon Rectum 2012; 55: 1213-1219 [PMID: 23135578 DOI:10.1097/DCR.0b013e318270837f]
20. Daly ME, Kapp DS, Maxim PG, Welton ML, Tran PT, Koong AC, Chang DT. Orthovoltage intraoperative radiotherapy for locally advanced and recurrent colorectal cancer. Dis Colon Rectum 2012; 55: 695-702 [PMID: 22595850 DOI: 10.1097/ DCR.0b013e31824d464c]
21. Tanis PJ, Doeksen A, van Lanschot JJ. Intentionally curative treatment of locally recurrent rectal cancer: a systematic review. Can J Surg 2013; 56: 135-144 [PMID: 23517634 DOI:10.1503/cjs.025911]
22. Mao C, Zhou J, Yang Z, Huang Y, Wu X, Shen H, Tang J, Chen Q. KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer. PLoS One 2012; 7: e36653 [PMID: 22586484 DOI: 10.1371/ journal.pone.0036653]
23. Hsieh LL, Er TK, Chen CC, Hsieh JS, Chang JG, Liu TC. Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population. Clin Chim Acta 2012; 413: 1605-1611 [PMID: 22579930 DOI: 10.1016/j.cca.2012.04.029]
24. De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 2011; 12: 594-603 [PMID: 21163703 DOI:10.1016/S1470-2045(10)70209-6]
25. Deevi R, Fatehullah A, Jagan I, Nagaraju M, Bingham V, Campbell FC. PTEN regulates colorectal epithelial apoptosis through Cdc42 signalling. Br J Cancer 2011; 105: 1313-1321 [PMID: 21952626 DOI: 10.1038/bjc.2011.384]
26. Naguib A, Cooke JC, Happerfield L, Kerr L, Gay LJ, Luben RN, Ball RY, Mitrou PN, McTaggart A, Arends MJ. Alterations in PTEN and PIK3CA in colorectal cancers in the EPIC Norfolk study: associations with clinicopathological and dietary factors. BMC Cancer 2011; 11: 123 [PMID: 21473780 DOI: 10.1186/1471-2407-11-123]
27. Hsu CP, Kao TY, Chang WL, Nieh S, Wang HL, Chung YC. Clinical significance of tumor suppressor PTEN in colorectal carcinoma. Eur J Surg Oncol 2011; 37: 140-147 [PMID: 21194879 DOI: 10.1016/j.ejso.2010.12.003]
28. Jang KS, Song YS, Jang SH, Min KW, Na W, Jang SM, Jun YJ, Lee KH, Choi D, Paik SS. Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma. Histopathology 2010; 56: 229-239 [PMID: 20102402 DOI:10.1111/j.1365-2559.2009.03468.x]
29. Watanabe T, Semba S, Yokozaki H. Regulation of PTEN expression by the SWI/SNF chromatin-remodelling protein BRG1 in human colorectal carcinoma cells. Br J Cancer 2011; 104: 146-154 [PMID: 21102582 DOI: 10.1038/sj.bjc.6606018]
30. Song M, Chen D, Lu B, Wang C, Zhang J, Huang L, Wang X, Timmons CL, Hu J, Liu B, Wu X, Wang L, Wang J, Liu H. PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. PLoS One 2013; 8: e65821 [PMID: 23785454 DOI: 10.1371/journal.pone.0065821]
31. Zhang CZ, Han L, Zhang AL, Fu YC, Yue X, Wang GX, Jia ZF, Pu PY, Zhang QY, Kang CS. MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. BMC Cancer 2010; 10: 367 [PMID: 20618998 DOI: 10.1186/1471-2407-10-367]
32. Spahn M, Kneitz S, Scholz CJ, Stenger N, Rüdiger T, Ströbel P, Riedmiller H, Kneitz B. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer 2010; 127: 394-403 [PMID: 19585579 DOI: 10.1002/ijc.24715]
33. Fornari F, Gramantieri L, Ferracin M, Veronese A, Sabbioni S, Calin GA, Grazi GL, Giovannini C, Croce CM, Bolondi L, Negrini M. MiR-221 controls CDKN1C/p57 and CDKN1B/ p27 expression in human hepatocellular carcinoma. Oncogene 2008; 27: 5651-5661 [PMID: 18521080 DOI: 10.1038/ onc.2008.178]
34. Rossi S, Calin GA. Bioinformatics, non-coding RNAs and its possible application in personalized medicine. Adv Exp Med Biol 2013; 774: 21-37 [PMID: 23377966 DOI: 10.1007/978-94-0 07-5590-1_2]
35. Sun K, Guo C, Deng HJ, Dong JQ, Lei ST, Li GX. Construction of lentivirus-based inhibitor of hsa-microRNA-338-3p with specific secondary structure. Acta Pharmacol Sin 2013; 34: 167-175 [PMID: 23202799 DOI: 10.1038/aps.2012.172]
36. Schetter AJ, Okayama H, Harris CC. The role of microRNAs in colorectal cancer. Cancer J 2012; 18: 244-252 [PMID: 22647361 DOI: 10.1097/PPO.0b013e318258b78f]